Early versus Later Anticoagulation for Stroke with Atrial Fibrillation
- PMID: 37222476
- DOI: 10.1056/NEJMoa2303048
Early versus Later Anticoagulation for Stroke with Atrial Fibrillation
Abstract
Background: The effect of early as compared with later initiation of direct oral anticoagulants (DOACs) in persons with atrial fibrillation who have had an acute ischemic stroke is unclear.
Methods: We performed an investigator-initiated, open-label trial at 103 sites in 15 countries. Participants were randomly assigned in a 1:1 ratio to early anticoagulation (within 48 hours after a minor or moderate stroke or on day 6 or 7 after a major stroke) or later anticoagulation (day 3 or 4 after a minor stroke, day 6 or 7 after a moderate stroke, or day 12, 13, or 14 after a major stroke). Assessors were unaware of the trial-group assignments. The primary outcome was a composite of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death within 30 days after randomization. Secondary outcomes included the components of the composite primary outcome at 30 and 90 days.
Results: Of 2013 participants (37% with minor stroke, 40% with moderate stroke, and 23% with major stroke), 1006 were assigned to early anticoagulation and 1007 to later anticoagulation. A primary-outcome event occurred in 29 participants (2.9%) in the early-treatment group and 41 participants (4.1%) in the later-treatment group (risk difference, -1.18 percentage points; 95% confidence interval [CI], -2.84 to 0.47) by 30 days. Recurrent ischemic stroke occurred in 14 participants (1.4%) in the early-treatment group and 25 participants (2.5%) in the later-treatment group (odds ratio, 0.57; 95% CI, 0.29 to 1.07) by 30 days and in 18 participants (1.9%) and 30 participants (3.1%), respectively, by 90 days (odds ratio, 0.60; 95% CI, 0.33 to 1.06). Symptomatic intracranial hemorrhage occurred in 2 participants (0.2%) in both groups by 30 days.
Conclusions: In this trial, the incidence of recurrent ischemic stroke, systemic embolism, major extracranial bleeding, symptomatic intracranial hemorrhage, or vascular death at 30 days was estimated to range from 2.8 percentage points lower to 0.5 percentage points higher (based on the 95% confidence interval) with early than with later use of DOACs. (Funded by the Swiss National Science Foundation and others; ELAN ClinicalTrials.gov number, NCT03148457.).
Copyright © 2023 Massachusetts Medical Society.
Similar articles
-
Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation: Post Hoc Analysis of the ELAN Randomized Clinical Trial.JAMA Neurol. 2024 Jul 1;81(7):693-702. doi: 10.1001/jamaneurol.2024.1450. JAMA Neurol. 2024. PMID: 38805207 Clinical Trial.
-
Early Versus Late Initiation of Direct Oral Anticoagulants After Ischemic Stroke in People With Atrial Fibrillation and Hemorrhagic Transformation: Prespecified Subanalysis of the Randomized Controlled ELAN Trial.Circulation. 2024 Jul 2;150(1):19-29. doi: 10.1161/CIRCULATIONAHA.124.069324. Epub 2024 May 16. Circulation. 2024. PMID: 38753452 Clinical Trial.
-
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.JAMA. 2021 Dec 21;326(23):2395-2404. doi: 10.1001/jama.2021.21222. JAMA. 2021. PMID: 34932078 Free PMC article.
-
Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin.Clin Cardiol. 2013 Feb;36(2):61-7. doi: 10.1002/clc.22081. Epub 2013 Jan 21. Clin Cardiol. 2013. PMID: 23338902 Free PMC article. Review.
-
Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation.Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):711-9. doi: 10.1161/CIRCOUTCOMES.112.966572. Epub 2012 Aug 21. Circ Cardiovasc Qual Outcomes. 2012. PMID: 22912382 Review.
Cited by
-
Challenging anticoagulation decisions in atrial fibrillation: a narrative review.Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447241290429. doi: 10.1177/17539447241290429. Ther Adv Cardiovasc Dis. 2024. PMID: 39413210 Free PMC article. Review.
-
Timing of oral anticoagulation in atrial fibrillation patients after acute ischaemic stroke and outcome after 3 months: results of the multicentre Berlin Atrial Fibrillation Registry.Open Heart. 2024 Sep 18;11(2):e002688. doi: 10.1136/openhrt-2024-002688. Open Heart. 2024. PMID: 39299734 Free PMC article.
-
Before, during, and after: An Argument for Safety and Improved Outcome of Thrombolysis in Acute Ischemic Stroke with Direct Oral Anticoagulant Treatment.Ann Neurol. 2024 Nov;96(5):871-886. doi: 10.1002/ana.27058. Epub 2024 Sep 11. Ann Neurol. 2024. PMID: 39258443 Review.
-
Contemporary Statistics of Acute Ischemic Stroke and Transient Ischemic Attack in 2021: Insights From the CRCS-K-NIH Registry.J Korean Med Sci. 2024 Sep 2;39(34):e278. doi: 10.3346/jkms.2024.39.e278. J Korean Med Sci. 2024. PMID: 39228188 Free PMC article. Review.
-
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Comprehensive Review.Cureus. 2024 Jul 25;16(7):e65347. doi: 10.7759/cureus.65347. eCollection 2024 Jul. Cureus. 2024. PMID: 39184779 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
